From novel biologics for rare diseases to AI-powered lab automation, from de-risking pharma exports to Drugs Controller General’s blueprint for a Viksit Bharat — analytica Lab India x PharmaCore India 2026 delivered the most analytically dense three days Mumbai’s pharmaceutical and laboratory science community has seen in a generation, Rashmi Kumari of Neo Science Hub reports from Mumbai
There is a particular quality of organised intensity that distinguishes a world-class trade fair from a mere industry gathering. analytica Lab India x PharmaCore India 2026 — the co-located, three-day convergence of South Asia’s foremost laboratory technology fair and West India’s dedicated pharmaceutical value-chain marketplace — had that quality from the moment the glass doors of the Jio World Convention Centre opened on the morning of April 22.
By the time they closed on the afternoon of April 24, something significant had happened at Bandra Kurla Complex. More than 8,000 professionals — laboratory scientists, quality heads, R&D directors, regulatory affairs managers, procurement executives, export merchants, startup founders, and a generation of young scientists discovering their vocational future — had passed through three interconnected pavilions totalling approximately 10,000 square metres of exhibition and conference space. More than 200 exhibitors had made their cases. And a carefully constructed three-day knowledge programme had traced, in real time, the full arc of where India’s pharmaceutical and laboratory science industries stand in 2026 — and where they must go.
A SIGNAL TO THE INDUSTRY
The opening ceremony on Day 1 was deliberate in its symbolism. When Shri Dilip Shanghvi — founder of Sun Pharmaceutical Industries, India’s largest pharma company by market capitalisation and a global top-five generics player — stepped up to formally inaugurate the co-located fairs, the choice said something significant about the organisers’ intent. This was not an event whose ambitions were limited to instrument sales and booth conversations. It was positioning itself as the venue where the strategic direction of India’s pharmaceutical and laboratory science industry is openly argued, interrogated, and, where possible, resolved.
Alongside Shanghvi on the inaugural dais stood Mr. Bhupinder Singh, President IMEA and CEO of Messe München — the Munich-headquartered global trade fair giant whose analytica brand is the world’s leading platform for laboratory, analytical, and biotechnology sectors — and Mr. Bharat Shah, National President of the Indian Drug Manufacturers Association (IDMA), the industry body that co-organises PharmaCore India. Mr. Deepak Parab, Vice President of the Indian Analytical Instruments Association, completed a quartet whose institutional range — spanning global event management, domestic drug manufacturing, and instruments industry representation — was itself a statement of the co-located fair’s breadth.
Social media posts from the organisers on Day 1 described it as “South Asia’s most anticipated lab and pharma event,” and the energy on the exhibition floor by mid-morning — booths packed, demonstrators mid-pitch, corridors alive with the directional movement of people who know where they are going — supported that claim.
THE EXHIBITION FLOOR: 200+ EXHIBITORS, ONE COHERENT STORY
Walking the three pavilions of the Jio World Convention Centre across three days, it becomes clear that the exhibitor profile of analytica Lab India x PharmaCore India 2026 is not a random collection of companies seeking booth space. It is, when read carefully, a remarkably complete map of the Indian pharmaceutical and laboratory science value chain — from the raw materials that go into a drug molecule, through the instruments used to characterise and control it, to the packaging that keeps it stable until it reaches a patient, and the digital systems that ensure the entire chain is documented, compliant, and auditable.
The Innovation Launch Pad and Software Pavilion
The Innovation Launch Pad — which unveiled more than 120 new product breakthroughs with live demonstrations — was among the most visited destinations on the analytica Lab India floor across all three days. In a sector where the pace of analytical technology development is accelerating faster than most laboratories’ ability to evaluate and adopt, a curated showcase of what is new and what matters is a genuine service to the scientific community. Companies used the Launch Pad to debut products ranging from next-generation spectroscopic platforms to AI-enabled bioprocess control systems to miniaturised assay preparation devices that eliminate the manual pipetting bottlenecks that slow high-throughput laboratory workflows.
The Software Pavilion addressed a different but equally urgent need: the digitisation of pharmaceutical quality systems. The co-location of laboratory informatics vendors (LIMS, DMS, QMS, LMS), validation lifecycle management platforms, supply chain AI, and ERP systems specifically designed for pharmaceutical manufacturers in a single dedicated zone created a rare opportunity for quality and IT decision-makers to evaluate the full landscape of digital compliance infrastructure in a single day’s walk.
Analytical Instruments: The Full Spectrum
The analytical instruments floor represented the full technical spectrum of what modern laboratory science requires. Shimadzu India’s Nexis GC-2060 brought Multi-Mode Injection capability and redesigned FID/TCD detectors that the company positioned as the most sensitive configuration currently available for pharmaceutical residual solvent and impurity analysis. Metrohm’s i-Raman NxG demonstrated instantaneous, preparation-free Raman spectroscopic analysis — eliminating the sample preparation bottleneck that makes traditional QC methods a production-floor liability. Analytik Jena presented both the PULSEspencer R automated assay preparation system and the multi N/C 4300 TOC analyser for pharmaceutical ultrapure water, while Hitachi High-Tech’s LA8080 AminoSAAYA brought a 30-per-cent-smaller amino acid analyser with ergonomic redesign and dual-liquid mixing that eliminates reagent refrigeration requirements.
SYMPATEC India’s particle size and shape analysis portfolio — spanning laser diffraction, high-speed image analysis, dry dispersion, and dynamic light scattering across a measurement range from sub-micron to 34,000 microns — covered the full spectrum of pharmaceutical solid dosage development needs. Hanna Equipments India’s HI932 automatic potentiometric titration system addressed the titration automation requirements of API testing laboratories. YK Analytical Corporation’s Freezing Point Osmometer served the osmolality measurement needs of injectable formulation and cell culture quality control. And Anton Paar’s presence at the fair — one of several international precision measurement instrument companies whose Mumbai exhibition announcements drove pre-registration traffic — underlined the genuinely international character of the analytica Lab India exhibitor profile.
Laboratory Infrastructure: The Unglamorous Essential
Some of the most significant products at the fair received the least attention in industry media precisely because their importance is invisible until they fail. Kesar Control Systems’ stability chambers and Labtop Instruments’ Waterless Stability Chamber represent the environmental simulation infrastructure on which every drug’s shelf-life claim ultimately rests — and Labtop’s waterless technology, which eliminates the reservoir-based contamination and scaling risks of conventional chambers, addresses a maintenance failure mode that has compromised regulatory audit outcomes at Indian manufacturing sites. iGene Labserve’s Single Lever Autoclave and Triple Deck Incubator Shaker demonstrated that thoughtful engineering of routine laboratory equipment — hydraulic lid control, integrated multi-parameter environmental management — can meaningfully reduce both operator fatigue and experimental variability. Mehrotra Biotech’s comprehensive laboratory cold-chain and thermal processing portfolio covered the full refrigeration spectrum from standard laboratory refrigerators through minus-20°C deep freezers to minus-86°C ultra-low-temperature systems — the complete biosample preservation infrastructure that any serious biologics or cell biology laboratory requires under one manufacturer’s quality umbrella.
M/s Metacryo Pvt. Ltd.’s AI-powered cryogenic storage system — the first fully indigenous Made in India cryogenic storage solution — deserves particular mention. Claiming the lowest nitrogen evaporation rate globally, with automated level and temperature management, remote monitoring, and vapor-phase storage below minus-139°C, it represents a genuine Indian engineering achievement in a product category previously dominated entirely by imports.
Sterility and Containment: The Safety Infrastructure
Svan Analytical Instruments’ comprehensive sterility and containment portfolio — Sterility Test Isolator, Glow Leak Tester, the Astracec CCIT system for IV bags using Probe Position Decay technology for non-destructive leak detection down to one micron, and the three-tier ZHEROX biodecontamination family spanning portable B-pack through room-scale Light to fully automated Fixed System — constituted the most coherent single-exhibitor containment and sterility assurance offering at the entire fair. For a sector in which contamination failures are not quality statistics but patient safety events, the comprehensiveness of Svan’s portfolio was noted by visitors across all three days.
Erweka India’s RoboDis II+ fully automated dissolution system — the only fully automatic dissolution tester on the market capable of running 40 batches in genuine 24/7 operation with computer-controlled processes that eliminate human intervention — addressed the quality control laboratory’s productivity challenge in a way that directly improves batch release throughput without sacrificing analytical rigour.
The Pharma Value Chain: Breadth and Depth
PharmaCore India’s exhibitor profile was the most diverse of the three pavilions, and deliberately so. ACG’s integrated OSD manufacturing proposition, Stallion Laboratories’ multi-therapeutic branded formulation portfolio, Montage Laboratories’ women’s health injectable and oral range, Indoco Remedies’ analytical and clinical services offering, INGA Pharmaceuticals’ 50-year specialist formulation track record, and Synokem’s six-facility CDMO platform collectively demonstrated the range of India’s pharmaceutical manufacturing capability across every dosage form and therapeutic category.
The excipient exhibitors — Gattefosse India’s lipidic functional excipient portfolio addressing bioavailability challenges, Nitika Pharmaceutical Specialities’ MCC and Magnesium Stearate presentations, and the EXCiPACT certification discussion from Day 2’s conference — framed excipients not as passive manufacturing inputs but as active formulation tools whose quality and functional characterisation directly determine whether drugs perform as designed. CN Water Systems’ high-purity water solutions, MSB Chemical’s US-DMF grade indigenous pharmacopoeial ethanol, and TM MEDIA’s 2,500-plus dehydrated culture media formulations completed the raw materials and process infrastructure picture.
The digital layer of PharmaCore — ValGenesis’ Smart GxP Platform for AI-enabled validation lifecycle management, OASIS I-TECH’s LIMS and compliance software ecosystem, Soham ERP Solutions’ pharma-specific software suite, and SYNC Consulting’s InfinitySync AI/ML supply chain platform — together made the argument that digitisation is no longer a technology investment decision for Indian pharmaceutical manufacturers. It is a regulatory compliance imperative, a competitive differentiation driver, and, increasingly, a market access prerequisite for the regulated export markets that India’s pharmaceutical ambitions require.
A STRONG FINISH
The organisers described Day 3’s close as a “strong finish to three days of discovery, innovation and scientific exchange,” and characterised the event overall as delivering “deep engagement across laboratory science, diagnostics, biotech and automation” and “valuable buyer-seller conversations” through to the final afternoon. Social media footage from multiple exhibitors showed busy booths, live demonstrations, and sustained aisle traffic on all three days — qualitative evidence of an event that met its footfall and engagement targets.
Precise post-event audited numbers for visitor counts and B2B conversion outcomes had not been publicly disclosed as of the close of the fair on April 24. The organiser’s pre-event projections of 8,000-plus professional visitors, 200-plus exhibitors, and 100-plus hosted buyers represent the scale at which the event was designed to operate; the observable floor energy across all three days was consistent with those projections.
The co-location of analytica Lab India and PharmaCore India is a structural statement: the laboratory scientist and the pharmaceutical manufacturer are, increasingly, participants in the same supply chain, solving the same problem.
What it was observed across three days at BKC was something more than a successful trade fair. It was an industry — fragmented, pressured, ambitious, and increasingly self-aware — using a common forum to take stock of where it stands and where it must go. The progression from ‘Powering Biopharma’ through ‘Lab 5.0’ to ‘From India to the World’ was not merely a conference theme sequence. It was a narrative about an industry in transition: from follower to originator, from reactive to predictive, from domestic-compliance-focused to globally competitive.
The next edition of analytica Lab India and PharmaCore India will be watched for whether that conversation produced commitments — in investment, in policy, in research programmes, in export market diversification — that outlast the three days at Jio World Convention Centre. The evidence from Mumbai in April 2026 is that the conversation is, at minimum, being conducted at the right level of seriousness.
